CN118354794A - Kras g12d抑制剂与伊立替康的组合及相关治疗方法 - Google Patents

Kras g12d抑制剂与伊立替康的组合及相关治疗方法 Download PDF

Info

Publication number
CN118354794A
CN118354794A CN202280077625.0A CN202280077625A CN118354794A CN 118354794 A CN118354794 A CN 118354794A CN 202280077625 A CN202280077625 A CN 202280077625A CN 118354794 A CN118354794 A CN 118354794A
Authority
CN
China
Prior art keywords
kras
irinotecan
pharmaceutically acceptable
inhibitor
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280077625.0A
Other languages
English (en)
Chinese (zh)
Inventor
吉尔·哈林
詹姆斯·盖尔·克里斯滕森
薇琪·鲍卡特
彼得·奥尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of CN118354794A publication Critical patent/CN118354794A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280077625.0A 2021-10-05 2022-10-04 Kras g12d抑制剂与伊立替康的组合及相关治疗方法 Pending CN118354794A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252405P 2021-10-05 2021-10-05
US63/252,405 2021-10-05
PCT/US2022/045625 WO2023059600A1 (en) 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with irinotecan and related methods of treatment

Publications (1)

Publication Number Publication Date
CN118354794A true CN118354794A (zh) 2024-07-16

Family

ID=85803676

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280077625.0A Pending CN118354794A (zh) 2021-10-05 2022-10-04 Kras g12d抑制剂与伊立替康的组合及相关治疗方法

Country Status (10)

Country Link
US (1) US20250249003A1 (https=)
EP (1) EP4412720A4 (https=)
JP (1) JP2024537137A (https=)
KR (1) KR20240073115A (https=)
CN (1) CN118354794A (https=)
AU (1) AU2022361219A1 (https=)
CA (1) CA3233571A1 (https=)
IL (1) IL311863A (https=)
MX (1) MX2024004214A (https=)
WO (1) WO2023059600A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Also Published As

Publication number Publication date
IL311863A (en) 2024-06-01
KR20240073115A (ko) 2024-05-24
CA3233571A1 (en) 2023-04-13
JP2024537137A (ja) 2024-10-10
EP4412720A1 (en) 2024-08-14
WO2023059600A1 (en) 2023-04-13
MX2024004214A (es) 2024-07-29
EP4412720A4 (en) 2025-08-13
US20250249003A1 (en) 2025-08-07
AU2022361219A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
CN118354794A (zh) Kras g12d抑制剂与伊立替康的组合及相关治疗方法
CN118382459A (zh) Kras g12d抑制剂与sos1抑制剂的组合疗法
JP2025148403A (ja) 組み合わせ療法
JP2022500384A (ja) 組み合わせ療法
JP2022500385A (ja) 組み合わせ療法
US20240408098A1 (en) COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT
JP2022500388A (ja) 組み合わせ療法
CN118401254A (zh) Kras g12d抑制剂与shp-2抑制剂的组合疗法
TW202313050A (zh) 組合療法
US20250177410A1 (en) Combination therapies comprising a sos1 inhibitor and an egfr inhibitor
CN115397514A (zh) 大环化合物的治疗用途
TW201343169A (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
HK40108579A (zh) Kras g12d抑制剂与伊立替康的组合及相关治疗方法
HK40108895A (zh) Kras g12d抑制剂与pi3ka抑制剂的组合及相关治疗方法
HK40109896A (zh) Kras g12d抑制剂与shp-2抑制剂的组合疗法
TW202428280A (zh) 組合療法
HK40109895A (zh) Kras g12d抑制剂与sos1抑制剂的组合疗法
TW201808300A (zh) σ受體配體在癌症中的用途
CN117615762A (zh) 组合疗法
HK40101229A (zh) 组合疗法
HK40074319A (en) Combination therapies
HK40109894A (zh) Kras g12d抑制剂与泛erbb家族抑制剂的组合疗法
BRPI0620209A2 (pt) tratamento de tumores resistentes a fármacos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40108579

Country of ref document: HK